FierceBiotech

Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock ...
FierceBiotech

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Yahoo Finance

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
PharmiWeb

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a ...